Non-small-cell lung carcinoma

Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors

Retrieved on: 
Monday, August 16, 2021
Apoptosis, Turning Point, NASDAQ, JAK2, Cancer, Cytokine, SRC, SAN, ROS1, Large-cell lung carcinoma, MET, Private Securities Litigation Reform Act, American Association, ALK, COVID-19, Therapy, GLOBE, Pharmacokinetics, SEC, Patient, Neoplasm, FAK, Non-small-cell lung carcinoma, Form 10-Q, Association, KRAS, TRK, Safety, Induced cell cycle arrest, EML4-ALK positive lung cancer, Pharmaceutical industry, Medical imaging

The initial cohort will investigate repotrectinib in combination with MEK-inhibitor trametinib in KRAS G12D mutated advanced solid tumors.

Key Points: 
  • The initial cohort will investigate repotrectinib in combination with MEK-inhibitor trametinib in KRAS G12D mutated advanced solid tumors.
  • The Phase 1b portion of the study will examine the safety, tolerability, pharmacokinetics, and any early signals of efficacy of repotrectinib in combination with trametinib in patients with KRAS G12D mutated advanced solid tumors.
  • After determination of a recommended Phase 2 combination dose, the study includes a Phase 2 dose expansion portion with the primary endpoint of objective response rate.
  • Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Merus Announces Financial Results for the Second Quarter and Provides Business Update

Retrieved on: 
Thursday, August 5, 2021
Collaboration, Asco, Industry, American Society of Clinical Oncology, Pancreatic cancer, IP, Response evaluation criteria in solid tumors, Large-cell lung carcinoma, Cancer, Lilly, Patient, Nature Communications, EAP, Neuregulin 1, Society, Â, Eli Lilly and Company, Non-small-cell lung carcinoma, Awareness, Travel, Research, Income, EGFR, Annual general meeting, Zeno, GLOBE, Pharmaceutical industry, Medical imaging, Health insurance

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced financial results for the second quarter that ended June 30, 2021 and provided a business update.

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced financial results for the second quarter that ended June 30, 2021 and provided a business update.
  • We plan to provide an update at a medical conference in the fourth quarter of 2021.
  • We plan to provide an update at a medical conference in the fourth quarter of 2021.
  • We ended the second quarter with cash, cash equivalents and marketable securities of $352.8 million compared to $207.8 million at December 31, 2020.

NextCure Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 5, 2021
Lung, Yale University, Research, U.S. Securities and Exchange Commission, Forward-looking statement, Asco, Mouse, Annual report, Large-cell lung carcinoma, Private Securities Litigation Reform Act, Hope, Program, Language, VTCN1, Patient, Growth, COVID-19, Tumor microenvironment, B cell, GLOBE, Society, Cancer, Sale, Non-small-cell lung carcinoma, Clinical Laboratory Improvement Amendments, Nasdaq, Survival, Terminology, Head, Marketing, Security (finance), American Society of Clinical Oncology, Pharmaceutical industry, Vaccine, Lithium

BELTSVILLE, Md., Aug. 05, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2021 financial results and provided a business update.

Key Points: 
  • BELTSVILLE, Md., Aug. 05, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2021 financial results and provided a business update.
  • Financial Results for Quarter Ended June 30, 2021
    Cash, cash equivalents and marketable securities as of June 30, 2021 were $249.5 million, compared to $283.4 million as of December 31, 2020.
  • Research and development expenses were $11.9 million for the quarter ended June 30, 2021, as compared to $11.1 million for the quarter ended June 30, 2020.
  • Net loss was $18.0 million for the quarter ended June 30, 2021, as compared to $14.5 million for the quarter ended June 30, 2020.

Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

Retrieved on: 
Thursday, August 5, 2021
Company, Investor, Cystic Fibrosis Foundation, Research, NT5E, Investment, Webcast, U.S. Securities and Exchange Commission, Asco, American Society of Clinical Oncology, Mutation, Development, Private Securities Litigation Reform Act, Risk, Broad, Large-cell lung carcinoma, Arginase, Consortium, PFS, Patient, Security (finance), Conference, Therapy, Commercialization, Biomarker, Society, Pemetrexed, Cancer, CALA, Carboplatin, NFE2L2, Data, Non-small-cell lung carcinoma, Cystic fibrosis, SAN, Pembrolizumab, Neoplasm, Adult, ID, Cabozantinib, Nasdaq, Doctor of Philosophy, KEAP1, Safety, RCC, Annual general meeting, Â, GLOBE, Cryptocurrency, Pharmaceutical industry, Tutoring

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Calithera anticipates releasing interim data from the KEAPSAKE trial in the fourth quarter of 2021.
  • Revenue was $3.0 million for the three months ended June 30, 2021 and represents revenue recognized in the second quarter from the companys license agreement with Antengene.
  • Research and development expenses for the second quarter 2021 were $12.8million, compared to $15.6million in the same period prior year.
  • General and administrative expenses for the second quarter 2021 were $4.5million, compared to $5.1million in the same period prior year.

Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights

Retrieved on: 
Thursday, August 5, 2021
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Company, Lung, Cancer, RDE, Chief executive officer, Research, List of life sciences, NT5E, Investment, Orr, Population, Pancreatic cancer, PFS, IND, Partnership, TKI, Autumn, Patient, Board, Docetaxel, Data, Non-small-cell lung carcinoma, New York Stock Exchange, Prostate, Prostate cancer, AstraZeneca, MCRPC, D, NP, Board of directors, Safety, Colon, Conference, Pharmaceutical industry, Medical imaging

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the second quarter ended June 30, 2021 and provided operational highlights.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the second quarter ended June 30, 2021 and provided operational highlights.
  • Based on this dataset, Arcus and Gilead will continue preparations for additional Phase 3 studies of dom-based combinations.
  • Results from the interim analysis for ARC-7 are expected to be submitted later this year for a presentation in 4Q21 or in 1H22.
  • Management will host a conference call today, August 5, 2021 to discuss second quarter 2021 financial results and recent corporate highlights.

Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates

Retrieved on: 
Thursday, August 5, 2021
IOV, Health, Patent, IL-2, Method, PD-L1, Manuscript, Cryopreservation, Cervical cancer, Cancer, Non-small-cell lung carcinoma, SAN, Pembrolizumab, Poster, Safety, American Society of Clinical Oncology, Annual general meeting, Transcription activator-like effector nuclease, Asco, PBL, Metastasis, Melanoma, Annual report, Private Securities Litigation Reform Act, Food and Drug Administration, Research, Interim, Security (finance), Risk, Investor, Orr, Population, Technology, Growth, Perception, Til, Food, Nasdaq, GLOBE, U.S. Securities and Exchange Commission, Investment, American Journal of Clinical Oncology, Programmed cell death protein 1, Journal, Lymphatic system, Dor, Patient, COVID-19, Society, BLA, Information, Forward-looking statement, Pharmaceutical industry, Medical imaging, Animal

SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter 2021 financial results and corporate updates.

Key Points: 
  • SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter 2021 financial results and corporate updates.
  • Research and development expenses were$62.1 millionfor the second quarter endedJune 30, 2021, an increase of$12.8 millioncompared to$49.3 millionfor the second quarter endedJune 30, 2020.
  • General and administrative expenses were$19.3 millionfor the second quarter endedJune 30, 2021, an increase of$5.0 millioncompared to$14.4 millionfor the second quarter endedJune 30, 2020.
  • Iovance will host a conference call today at4:30 p.m. ETto discuss the second quarter 2021 financial results and corporate updates.

Combination of Experimental Drug Classes Shown to Extend Survival in Mice with Lung Cancer

Retrieved on: 
Thursday, August 5, 2021
New York University, Novartis, KRAS, New York University Grossman School of Medicine, Hematology, Toxicity, Cancer, Interleukin 8 receptor, beta, Department, Mek, BMS, Non-small-cell lung carcinoma, Neoplasm, Doctor of Philosophy, AstraZeneca, Survival, Clinical trial, Gerson Lehrman Group, Division, EGF, NYU Langone Health, Treatment of lung cancer, Merck, Food and Drug Administration, Protein, Therapy, MD, Chemokine, Department of Medicine – University of Pamplona, Novartis Institute for Tropical Diseases, G1 Therapeutics, Growth, Immune system, EGFR, Research, Regeneron Pharmaceuticals, Mouse, PTPN11, Virus, Biomedical Research, Patient, Alvin J. Siteman Cancer Center, Lung, Weakness, Cell, Vaccine, Pharmaceutical industry

NEW YORK, Aug. 5, 2021 /PRNewswire/ -- A combination of experimental drugs increased the attack of immune cells on non-small-cell lung cancer cells to extend survival in mice, a new study found.

Key Points: 
  • NEW YORK, Aug. 5, 2021 /PRNewswire/ -- A combination of experimental drugs increased the attack of immune cells on non-small-cell lung cancer cells to extend survival in mice, a new study found.
  • These findings showed that at least some T cells in these mice were capable of killing tumor cells.
  • The abundance of the gMDSCs in cancer patients have been linked by past studies to reduced overall survival in multiple solid tumor types.
  • He also has a sponsored research agreement with Mirati, and received consulting fees from MPM Capital and Gerson Lehrman Group.

 Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal™ Dx Lung and Colon Cancer Assay

Retrieved on: 
Thursday, August 5, 2021
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Pillar, Chief executive officer, IVD, Lung, NGS, Corporate development, KRAS, Large-cell lung carcinoma, Partnership, TKI, Eli Lilly, Health, Patient, Cetuximab, Cancer, PMA, Non-small-cell lung carcinoma, Merck, Food and Drug Administration, Precision medicine, Cdx, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CRC, Column, DNA, DX, Genome, EGFR, Food, Panitumumab, Medical imaging, Pharmaceutical industry, Pillar Biosciences, Pillar’s Technology Platform, PILLAR BIOSCIENCES, PILLAR’S TECHNOLOGY PLATFORM

Pillar Biosciences , an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the U.S. Food and Drug Administration (FDA) has given Premarket Approval (PMA) to its oncoReveal Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors.

Key Points: 
  • Pillar Biosciences , an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the U.S. Food and Drug Administration (FDA) has given Premarket Approval (PMA) to its oncoReveal Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors.
  • This panel is intended to be used on the Illumina MiSeq Dx instrument, Illuminas NGS platform for in vitro diagnostic testing.
  • We are committed to providing high quality and accurate IVD tests to enable better treatment decisions for cancer patients, said Gang Song, Ph.D., Founder and CEO at Pillar Biosciences.
  • Our FDA-approved product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients.

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021

Retrieved on: 
Thursday, August 5, 2021
Company, GlaxoSmithKline, Stomach, NT5E, U.S. Securities and Exchange Commission, Forward-looking statement, Asco, Large-cell lung carcinoma, American Society of Clinical Oncology, Novartis, Pancreatic cancer, Hepatocellular carcinoma, Annual report, Roche, Security (finance), Private Securities Litigation Reform Act, Bevacizumab, IND, ENTPD1, GSK, Patient, PVRIG, COVID-19, Drug discovery, Interleukin 27, Tumor microenvironment, Society, Non-small-cell lung carcinoma, Phase 1, Risk, HCC, CCR8 (gene), Renal cell carcinoma, Research, R, RCC, Annual general meeting, G&A, Corporation, GLOBE, Pharmaceutical industry

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2021, and provided an update on anticipated corporate milestones.

Key Points: 
  • The second quarter marked a major milestone for Surface, with SRF388 monotherapy eliciting the first-ever clinical response from a therapeutic targeting the IL-27 pathway.
  • On June 4, 2021, Surface presented preliminary data from the ongoing Phase 1 study of SRF388, an anti-IL-27 antibody, at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
  • R&D expenses included $0.9 million in stock-based compensation expense for the second quarter ended June30, 2021.
  • G&A expenses included $1.4 million in stock-based compensation expense for the second quarter ended June30, 2021.

TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 5, 2021
Acute lymphoblastic leukemia, The Retreat, Cancer, Non-small-cell lung carcinoma, Safety, Clinical trial, Tenant, Annual report, Private Securities Litigation Reform Act, Review, Thalassemia, ESMO, Oncology, Lung cancer, European Society for Medical Oncology, Research, Therapy, Risk, European Society of Gene and Cell Therapy, Transfusion, IND, Limited liability company, Partnership, TCR, Aall, Congress, National Hockey League, Oslo-Fergene, GLOBE, Company, Conference, U.S. Securities and Exchange Commission, Investment, Cholangiocarcinoma, Lymphatic system, Adoption, HLA, Program, Patient, COVID-19, Ovarian cancer, Certification, Adult, Nasdaq, D, Cell, Quality control, Pharmaceutical industry, Animal, Cryptocurrency

Net cash used in operations was $15.0 million for the second quarter of 2021 compared to $16.0 million for the second quarter of 2020.

Key Points: 
  • Net cash used in operations was $15.0 million for the second quarter of 2021 compared to $16.0 million for the second quarter of 2020.
  • R&D Expenses: Research and development expenses were $18.6 million for the second quarter of 2021 compared to $12.9 million for the second quarter of 2020.
  • G&A Expenses: General and administrative expenses were $5.7 million for the second quarter of 2021 compared to $3.8 million for the second quarter of 2020.
  • Net Loss: Net loss was $24.3 million for the second quarter of 2021 compared to $16.2 million for the second quarter of 2020.